AzTrials
AzTrials

Multiple MyelomaPhase 3TRIlogy-7NCT07665450

A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

A Phase 3 study testing Ramantamig, Daratumumab and Lenalidomide in people with Multiple Myeloma, run by Janssen Research & Development, LLC at 103 sites in 14 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The main purpose of this study is to see how well a new treatment ramantamig-D works compared to standard treatments that is either DVRd or DRd on progression-free survival (PFS; time until a participant's disease worsens) and 12-month minimal residue disease (MRD)-negative complete response (CR) rate (percentage of… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Multiple Myeloma
What is being tested?
Ramantamig, Daratumumab and Lenalidomide
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,000 participants
Where
103 sitesin 14 countries
Study dates
9 Sep 2026to 2 Feb 2035
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Documented diagnosis of multiple myeloma (MM) according to the IMWG diagnostic criteria
  • Not considered for high-dose chemotherapy with autologous stem cell transplantation (ASCT) due to: i. ineligible due to advanced age; or ii. ineligible due to presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT
  • Have an eastern cooperative oncology status (ECOG) performance status of 0 to 2
  • Must sign an informed consent form (ICF)
  • Measurable disease at screening as assessed by central laboratory as defined in the protocol

Who cannot join

  • Myeloma Frailty Score of greater than or equal to (>=) 2 with the exception of participants who have a score of 2 based on age alone
  • Suspected or known allergies, hypersensitivity, intolerance or other contraindications to any trial intervention or its excipients
  • Had major surgery (for example, requiring general anesthesia) or had significant traumatic injury within 2 weeks prior to first dose of trial intervention or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the trial
  • Known active or prior CNS involvement or exhibits clinical signs of meningeal involvement of MM
  • Received any prior therapy(ies) for treatment of MM or smoldering myeloma, with the exception of emergency use of a short course of corticosteroids

Trial locations and contacts

103 sites in 14 countries. Contact the study team or a site near you to ask about taking part.

Study Contact contact

844-434-4210

Participate-In-This-Study1@its.jnj.com

103 sites in 14 countries

Spain22 sites, 22 recruiting

  • Hosp. Univ. Germans Trias I Pujol

    Badalona, 08916

    Recruiting

  • Hosp. de La Santa Creu I Sant Pau

    Barcelona, 08025

    Recruiting

  • Hosp.Clinic and Provincial

    Barcelona, 08036

    Recruiting

  • Hosp. San Pedro de Alcantara

    Cáceres, 10003

    Recruiting

  • Hosp. Univ. Virgen de Las Nieves

    Granada, 18014

    Recruiting

  • Hosp. de Jerez de La Frontera

    Jerez de la Frontera, 11407

    Recruiting

  • Hosp. de Leon

    León, 24071

    Recruiting

  • Hosp. Univ. Lucus Augusti

    Lugo, 27003

    Recruiting

  • Hosp. Univ. de La Princesa

    Madrid, 28006

    Recruiting

  • Hosp. Gral. Univ. Gregorio Maranon

    Madrid, 28009

    Recruiting

  • Hosp. Univ. Infanta Leonor

    Madrid, 28031

    Recruiting

  • Hosp. Univ. Ramon Y Cajal

    Madrid, 28034

    Recruiting

  • Hosp. Univ. 12 de Octubre

    Madrid, 28041

    Recruiting

  • Hosp. Univ. La Paz

    Madrid, 28046

    Recruiting

  • Complejo Hosp. de Navarra 1

    Pamplona, 31008

    Recruiting

  • Complejo Hosp. de Navarra

    Pamplona, 31008

    Recruiting

  • Hosp. Quiron Madrid Pozuelo

    Pozuelo de Alarcón, 28223

    Recruiting

  • Hosp Clinico Univ de Salamanca

    Salamanca, 37007

    Recruiting

  • Hosp. Univ. Marques de Valdecilla

    Santander, 39008

    Recruiting

  • Hospital Universitario Virgen Rocio

    Seville, 41013

    Recruiting

  • Hosp. Univ. Dr. Peset

    Valencia, 46017

    Recruiting

  • Hosp. Clinico Univ. Lozano Blesa

    Zaragoza, 50009

    Recruiting

Other trials in Spain

Turkey (Türkiye)10 sites, 10 recruiting

  • Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi

    Ankara, 06200

    Recruiting

  • Ankara Universitesi Tip Fakultesi Cebeci Arastirma ve Uygulama Hastanesi

    Ankara, 06620

    Recruiting

  • Liv Hospital Ankara

    Ankara, 06680

    Recruiting

  • Memorial Antalya Hastanesi

    Antalya, 07025

    Recruiting

  • Akdeniz Universitesi Tip Fakultesi

    Antalya, 07070

    Recruiting

  • Koc Universitesi Hastanesi

    Istanbul, 34010

    Recruiting

  • Medipol Mega University Hospital

    Istanbul, 34214

    Recruiting

  • Istanbul Florence Nightingale Hastanesi

    Istanbul, 34381

    Recruiting

  • Izmir Tinaztepe Universitesi Ozel Galen Hastanesi

    Izmir, 35001

    Recruiting

  • Ondokuz Mayis University

    Samsun, 55139

    Recruiting

Other trials in Turkey (Türkiye)

France9 sites, 9 recruiting

  • Hopital Claude Huriez

    Lille, 59000

    Recruiting

  • CHU de Montpellier Hopital Saint Eloi

    Montpellier, 34295 cede

    Recruiting

  • CHU Nantes

    Nantes, 44000

    Recruiting

  • Aphp Hopital Saint Antoine

    Paris, 75012

    Recruiting

  • CHU de Bordeaux - Hospital Haut-Leveque

    Pessac, 33600

    Recruiting

  • CHU Lyon Sud

    Pierre-Bénite, 69495

    Recruiting

  • IUCT Oncopole Institut Claudius Regaud

    Toulouse, 31100

    Recruiting

  • CHRU Tours Hopital Bretonneau

    Tours, 37044

    Recruiting

  • CHU Nancy Brabois

    Vandœuvre-lès-Nancy, 54500

    Recruiting

Other trials in France

Poland9 sites, 9 recruiting

  • Jan Biziel's University Hospital

    Bydgoszcz, 85 168

    Recruiting

  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich

    Chorzów, 41-500

    Recruiting

  • Uniwersyteckie Centrum Kliniczne Uniwersytet Medyczny

    Gdansk, 80 214

    Recruiting

  • Pratia Onkologia Katowice

    Katowice, 40 519

    Recruiting

  • Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach

    Kielce, 25 734

    Recruiting

  • Pratia MCM Krakow

    Krakow, 30-727

    Recruiting

  • Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie

    Lublin, 20 081

    Recruiting

  • Uniwersytecki Szpital Kliniczny Nr 1 PUM im prof Tadeusza Sokolowskiego w Szczecinie

    Szczecin, 71-252

    Recruiting

  • Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu

    Wroclaw, 50 367

    Recruiting

Other trials in Poland

South Korea9 sites, 9 recruiting

  • National Cancer Center

    Gyeonggi-do, 10408

    Recruiting

  • Seoul National University Bundang Hospital

    Gyeonggi-do, 13620

    Recruiting

  • Chonnam National University Hwasun Hospital

    Jeollanam-do, 58128

    Recruiting

  • Seoul National University Hospital

    Seoul, 03080

    Recruiting

  • The Catholic University of Korea Eunpyeong St Marys Hospital

    Seoul, 03312

    Recruiting

  • Asan Medical Center

    Seoul, 05505

    Recruiting

  • Samsung Medical Center

    Seoul, 06351

    Recruiting

  • The Catholic University of Korea Seoul St Mary s Hospital

    Seoul, 06591

    Recruiting

  • Ulsan University Hospital

    Ulsan, 44033

    Recruiting

Other trials in South Korea

United Kingdom9 sites, 9 recruiting

  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham, B15 2GW

    Recruiting

  • Blackpool Victoria Hospital

    Blackpool, FY3 8NR

    Recruiting

  • Bristol NHS Foundation Trust

    Bristol, BS2 8ED

    Recruiting

  • Addenbrooke's Hospital

    Cambridge, CB2 0QQ

    Recruiting

  • Kent and Canterbury Hospital

    Canterbury, CT1 3NG

    Recruiting

  • Colchester Hospital University NHS

    Colchester, CO4 5JL

    Recruiting

  • Western General Hospital

    Edinburgh, EH4 2XU

    Recruiting

  • New Cross Hospital

    Heath Town, WV10 0QP

    Recruiting

  • University College Hospital

    London, NW1 2PG

    Recruiting

Other trials in United Kingdom

Czechia6 sites, 6 recruiting

  • Fakultni nemocnice Brno

    Brno, 625 00

    Recruiting

  • Fakultni nemocnice Hradec Kralove

    Hradec Králové, 500 05

    Recruiting

  • Fakultni Nemocnice Ostrava

    Ostrava, 708 52

    Recruiting

  • Fakultni nemocnice Plzen

    Pilsen, 304 60

    Recruiting

  • Fakultni nemocnice Kralovske Vinohrady

    Prague, 100 00

    Recruiting

  • Vseobecna fakultni nemocnice v Praze

    Prague, 128 00

    Recruiting

Other trials in Czechia

Greece6 sites, 6 recruiting

  • Uni General Hospital of Alexandroupolis

    Alexandroupoli, 681 00

    Recruiting

  • Evangelismos S A

    Athens, 106 76

    Recruiting

  • Laiko General Hospital of Athens

    Athens, 11526

    Recruiting

  • Alexandra General Hospital of Athens

    Athens, 11528

    Recruiting

  • Theageneio Cancer Hospital

    Thessaloniki, 54639

    Recruiting

  • Geniko Nosokomeio Thessalonikis George Papanikolaou

    Thessaloniki, 570 10

    Recruiting

Other trials in Greece

Israel6 sites, 6 recruiting

  • Rambam Med.Center - Hematology Institute

    Haifa, 3109601

    Recruiting

  • Carmel Medical Center

    Haifa, 3436212

    Recruiting

  • Shaare Zedek Medical Center

    Jerusalem, 9103102

    Recruiting

  • Rabin Medical Center

    Petah Tikva, 4941492

    Recruiting

  • Sheba Medical Center

    Ramat Gan, 5262000

    Recruiting

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, 64239

    Recruiting

Other trials in Israel

Netherlands5 sites, 5 recruiting

  • Catharina Ziekenhuis

    Eindhoven, 5623 EJ

    Recruiting

  • Universitair Medisch Centrum Groningen

    Groningen, 9713 GZ

    Recruiting

  • Sint Antonius Ziekenhuis

    Nieuwegein, 3435CM

    Recruiting

  • Zuyderland Medical Center

    Sittard-Geleen, 6162 BG

    Recruiting

  • UMCU

    Utrecht, 3584 CX

    Recruiting

Other trials in Netherlands

Italy4 sites, 4 recruiting

  • A O U Sant Orsola Malpighi

    Bologna, 40138

    Recruiting

  • S.C. Ematologia Azienda Ospedaliera S. Croce e Carle

    Cuneo, 12100

    Recruiting

  • Fondazione IRCCS Ca Granda Ospedale Policlinico Di Milano

    Milan, 20122

    Recruiting

  • Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone

    Palermo, 90127

    Recruiting

Other trials in Italy

Portugal4 sites, 4 recruiting

  • Uls Braga - Hosp. Braga

    Braga, 4710-243

    Recruiting

  • Fund. Champalimaud

    Lisbon, 1400 038

    Recruiting

  • Ipo Porto

    Porto, 4200 072

    Recruiting

  • Ulstmad - Hosp. Sao Pedro de Vila Real

    Vila Real, 5000 508

    Recruiting

Other trials in Portugal

Australia2 sites, 2 recruiting

  • St Vincent s Hospital Sydney

    Darlinghurst, 2010

    Recruiting

  • Mater Hospital Brisbane

    South Brisbane, 4101

    Recruiting

Other trials in Australia

Germany2 sites, 2 recruiting

  • St. Barbara-Klinik Hamm GmbH

    Hamm, 59073

    Recruiting

  • Universitaetsklinikum Wuerzburg

    Würzburg, 97080

    Recruiting

Other trials in Germany

About this study

Official title: A Phase 3 Randomized Study Comparing Ramantamig Plus Daratumumab Versus Investigator's Choice of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

The main purpose of this study is to see how well a new treatment ramantamig-D works compared to standard treatments that is either DVRd or DRd on progression-free survival (PFS; time until a participant's disease worsens) and 12-month minimal residue disease (MRD)-negative complete response (CR) rate (percentage of participants in whom cancer cells are not detected) in participants with newly diagnosed multiple myeloma (NDMM; an initial stage of blood cancer that forms in a type of white blood cells [WBCs] called plasma cells) for whom stem cell transplant is not planned as initial therapy.

Medical subject headings
Multiple Myeloma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • RamantamigDrug

    Ramantamig will be administered subcutaneously.

  • DaratumumabDrug

    Daratumumab will be administered subcutaneously.

  • LenalidomideDrug

    Lenalidomide will be administered orally.

  • BortezomibDrug

    Bortezomib will be administered subcutaneously or intravenously.

  • DexamethasoneDrug

    Dexamethasone will be administered orally or intravenously.

Study groups in NCT07665450
Study groupRoleWhat they receive
Arm A: Ramantamig plus Daratumumab (Ramantamig-D)ExperimentalParticipants will receive ramantamig D subcutaneous injection.
Receives: Drug: Ramantamig; Drug: Daratumumab
Arm B: Investigator's Choice (DVRd or DRd)Active comparatorParticipants will receive either daratumumab, bortezomib, lenalidomide, dexamethasone (DVRd) or daratumumab, lenalidomide, dexamethasone (DRd) as per investigator's choice.
Receives: Drug: Daratumumab; Drug: Lenalidomide; Drug: Bortezomib; Drug: Dexamethasone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Progression-Free Survival (PFS)

    PFS is defined as the duration from randomization to either confirmed progression of disease (PD) or death, whichever occurs first.

    Measured: Up to approximately 62 months

  2. Percentage of Participants Achieving 12-Month Minimal Residual Disease (MRD)-Negative Complete Response (CR)

    12-month MRD-negative CR rate is defined as participants who achieve MRD-negative status at 12 months (+/-3 months) from randomization, as determined by next-generation sequencing (NGS), prior to PD or subsequent antimyeloma therapy (including ASCT). Additionally, participant must achieve CR or better any time from randomization up to and including 12+3 months prior to PD or subsequent antimyeloma therapy, according to international myeloma working group (IMWG) criteria.

    Measured: Up to 12 months

Secondary outcomes (15)

  1. Overall Survival (OS)

    OS is defined as time from treatment assignment (that is, randomization in the trial) to date of death due to any cause.

    Measured: Up to approximately 100 months

  2. Percentage of Participants Achieving 24-Month Sustained MRD-Negative CR

    24-month sustained MRD-negative CR is defined as participants who achieve MRD-negative CR status, as determined by NGS for at least 24 months without any examination showing MRD positive status or PD in between.

    Measured: Up to 5 years

  3. Percentage of Participants with Very Good Partial Response (VGPR) or Better

    Percentage of participants achieving VGPR, CR, or stringent complete response (sCR) prior to subsequent antimyeloma therapy in accordance with IMWG criteria during or after the trial intervention will be reported.

    Measured: Up to 5 years

  4. Percentage of Participants with CR or Better

    Percentage of participants achieving CR, or sCR prior to subsequent antimyeloma therapy in accordance with IMWG criteria during or after the trial intervention will be reported.

    Measured: Up to 5 years

  5. Percentage of Participants with Overall Response

    Percentage of participants achieving PR or better prior to subsequent antimyeloma therapy in accordance with IMWG criteria during or after the trial intervention will be reported.

    Measured: Up to 5 years

  6. Percentage of Participants with Overall MRD-Negative CR

    Percentage of participants who achieve MRD-negative status, as determined by NGS at any time point after randomization and prior to PD or subsequent antimyeloma therapy and who achieve CR or better will be reported.

    Measured: Up to 5 years

  7. Percentage of Participants with 12-Month Sustained MRD-Negative CR

    Percentage of participants who achieve MRD-negative CR status, as determined by NGS, for at least 12 months without any examination showing MRD-positive status or PD in between will be reported.

    Measured: Up to 5 years

  8. Progression Free Survival After Subsequent Therapy (PFS2)

    PFS2 is defined as the time interval between the date of randomization and date of event, which is defined as PD as assessed by investigator on the first subsequent line of antimyeloma therapy, or death from any cause, whichever occurs first.

    Measured: Up to approximately 100 months

  9. Number of Participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical trial participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention.

    Measured: Up to approximately 100 months

  10. Change from Baseline in Health-Related Quality of Life (HRQoL) as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Scale Score

    The MySIm-Q is a disease-specific PRO assessment complementary to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30). It includes 17 items with recall period of "7 days" and responses are reported on a 5-point verbal rating scale. Item responses are scored from 0 to 4. Higher scores indicate greater severity/impact.

    Measured: Baseline up to approximately 100 months

  11. Change from Baseline in HRQoL as Assessed by EORTC-QLQ-C30 Scale Score

    The EORTC QLQ-C30 Version 3 includes 30 items that make up 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea/vomiting), and 5 single symptom items (dyspnea, insomnia, appetite loss, constipation, and diarrhea) and a single impact item (financial difficulties). The item and scale scores are transformed to a 0 to 100 scale. A higher score represents greater HRQoL, better functioning, and more (worse) symptoms.

    Measured: Baseline up to approximately 100 months

  12. Change from Baseline in HRQoL as Assessed by European Quality of Life - 5 Dimensions-5 Levels (EQ-5D-5L) Scale Score

    The EQ-5D-5L is a self-administered, generic health status measure, consisting of a descriptive system and a visual analog scale (EQ-VAS). The EQ-5D-5L descriptive system covers 5 dimensions of health (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression), each with 5 levels of severity (no problems, slight problems, moderate problems, severe problems, and unable to perform or extreme problems) with higher scores indicating worse HRQoL.

    Measured: Baseline up to approximately 100 months

  13. Change from Baseline in HRQoL as Assessed by Patient Global Impression of Symptom Severity (PGIS) Scale Score

    The PGI-S is a 2-item questionnaire that assesses severity of the participant's symptoms and impacts of their symptoms, respectively, on a 5-point verbal rating scale, at the time of completing the PRO measure. Score ranges from 1 (None) to 5 (Very Severe). Higher scores indicate greater severity.

    Measured: Baseline up to approximately 100 months

  14. Change from Baseline in HRQoL as Assessed by European Organization for Research and Treatment of Cancer Item List (EORTC IL) 46

    The EORTC IL46 consists of a single question that measures global impression of burden due to treatment-related symptoms. The response options range from "not at all" to "very much" on a 4 point scale where higher scores indicate more symptoms.

    Measured: Baseline up to approximately 100 months

  15. Percentage of Participants with Tolerability to Ramantamig-D Measured Through Patient Reported Outcomes (PROs)

    Percentage of participants with tolerability to ramantamig-D measured through PROs will be reported.

    Measured: Up to approximately 100 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jun 2026
  2. Study start9 Sep 2026
  3. Primary completion4 Sep 2030 (estimated)
  4. Study completion2 Feb 2035 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
1,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07665450
Sponsor's protocol ID
79635322MMY3004
Acronym
TRIlogy-7
Status last verified
Nov 2026
First submitted
18 Jun 2026
Last updated
3 Nov 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.jnj.com/innovativemedicine/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Ramantamig, Daratumumab and Lenalidomide in people with Multiple Myeloma, run by Janssen Research & Development, LLC at 103 sites in 14 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 3 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 103 sites in Spain, Turkey (Türkiye), France, Poland, South Korea and 9 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Study Contact (844-434-4210, Participate-In-This-Study1@its.jnj.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Progression-Free Survival (PFS) (time frame: Up to approximately 62 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07665450.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in